This study aims to investigate delta‐He, a novel marker reflecting the iron availability and inflammation through the difference in hemoglobin content between reticulocytes and erythrocytes, as a potential prognostic factor in patients with NSCLC undergoing PD‐1/PD‐L1 inhibitor therapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.